STTK trades 224.7% below Wall Street's consensus target of $15.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STTK achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 9, 2026, Shattuck Labs, Inc. (STTK) has a Wall Street consensus price target of $15.00, based on estimates from 9 covering analysts. With the stock currently trading at $4.62, this represents a potential upside of +224.7%. The company has a market capitalization of $418M.
Analyst price targets range from a low of $7.00 to a high of $19.00, representing a 80% spread in expectations. The median target of $16.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STTK trades at a trailing P/E of -12.5x. Analysts expect EPS to grow -19.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 NKTXNkarta, Inc. | $124M | $1.73 | $9.00 | +420.2% | Buy | — | 12 |
 CRISCuris, Inc. | $2M | $0.91 | — | — | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $9.2B | $59.83 | $80.50 | +34.6% | Buy | 59.8x | 13 |
 FATEFate Therapeutics, Inc. | $214M | $1.84 | $5.63 | +206.8% | Buy | — | 31 |
 ALNYAlnylam Pharmaceuticals, Inc. | $20.8B | $155.94 | $330.54 | +112.0% | Buy | 8.5x | 52 |
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 RVMDRevolution Medicines, Inc. | $40.9B | $192.28 | $253.47 | +31.8% | Buy | — | 25 |
Quick answers to the most common questions about buying STTK stock.
The consensus Wall Street price target for STTK is $15, representing 224.7% upside from the current price of $4.62. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STTK has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies 224.7% upside from current levels.
STTK's current price is $4.62 with a consensus target of $15 (224.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $19 for STTK, while the most conservative target is $7. The consensus of $15 represents the median expectation. These targets typically reflect 12-month expectations.
STTK is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STTK stock forecast based on 9 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $7 (bear case) to $19 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STTK, with a "Buy" consensus rating and $15 price target (224.7% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STTK analyst price targets range from $7 to $19, a 80% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.